TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

Summary: Colon cancer is one of the most common cancers in the world. When it spreads to other parts of the body, the usual treatments often stop working after a while. Doctors are testing a new medicine called sacituzumab govitecan (SG for short). It acts like a smart bomb, finding cancer cells with a special marker called TROP2 and delivering medicine straight to them. SG already works well for breast cancer. In this new study, called TROPHIT1, doctors are testing if SG can help people with advanced colon cancer who have already tried other treatments. They hope this new drug will stop the cancer from growing for a longer time.